research Cetuximab-induced hypertrichosis of the scalp and eyelashes
A cancer drug caused unusual hair growth on a 100-year-old man's scalp and eyelashes.
Search
for
Sort by
Research
540-570 / 1000+ results research Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
Early intervention and tailored management are crucial for skin side effects in cancer treatments.
research Vandetanib
A man developed alopecia areata after starting cancer treatment with vandetanib.
research Anthracycline analogs The past, present, and future
Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.
research Management of the adverse effects of targeted therapy for cancer
Targeted cancer therapies can cause new side effects, requiring careful monitoring and management to ensure patient safety.
research SUN-911 Immunotherapy Use in Adrenocortical Carcinoma with Encouraging Results- a Case Report
Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.
research 549 Temporary cell cycle arrest in human scalp hair follicles and their epithelial stem cells by ALRN-6924: A novel strategy to selectively protect p53-wildtype cells against paclitaxel-induced alopecia
ALRN-6924 may prevent hair loss caused by chemotherapy.
research Cytostatics and immunosuppressive drugs
Some cancer and immune system drugs can cause serious side effects, including heart, lung, nerve, and organ damage, which need careful monitoring and management.
research Topical botanical extract for management of chemotherapy-induced alopecia
A botanical extract may help manage hair loss from chemotherapy by preventing cell death in hair follicles.
research Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.
research A comparison of the cytotoxic effects of fatty acids on in vitro breast and prostate cell lines
DHA derivatives, especially didocosahexaenoin, effectively kill prostate cancer cells and may offer a safer cancer treatment option.
research Fabrication and in vitro evaluation of silk fibroin-folic acid decorated paclitaxel and hydroxyurea nanostructured lipid carriers for targeting ovarian cancer cells: A double sword approach
The new drug carriers show promise for better targeting and treating ovarian cancer.
research Persistent Chemotherapy-Induced Alopecia Treated With Low Dose Oral Minoxidil: A Multicenter Retrospective Case Series of 15 Patients
Low dose oral minoxidil helped treat long-term hair loss caused by chemotherapy in 15 patients.
research Trastuzumab Induced Chemobrain, Atorvastatin Rescued Chemobrain with Enhanced Anticancer Effect and without Hair Loss-Side Effect
Atorvastatin reversed memory problems caused by cancer drug trastuzumab and improved its cancer-fighting abilities without causing hair loss.
research Peroxisome proliferator-activated receptor-γ signalling protects hair follicle stem cells from chemotherapy-induced apoptosis and epithelial–mesenchymal transition
Activating PPAR-γ signalling can protect hair follicle stem cells from damage caused by chemotherapy.
research Advances in the Management of Cutaneous Toxicities of Targeted Therapies
Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.
research Studying combined effects of chemotherapy and radiotherapy on blood cell counts in lung cancer patients
Chemotherapy and radiotherapy improved quality of life and reduced symptoms in lung cancer patients.
research Modulation of Chemotherapy-Induced Human Hair Follicle Damage by 17-β Estradiol and Prednisolone: Potential Stimulators of Normal Hair Regrowth by “Dystrophic Catagen” Promotion?
17-β estradiol and prednisolone may speed up hair regrowth after chemotherapy.
research Trichomegaly of the eyelashes following treatment with cetuximab
Cetuximab can cause excessive eyelash growth.
research Lifestyle and Adiponectin Level: Four-Year Follow-up of Controlled Trials
Prostaglandins may protect hair follicles during chemotherapy.
research Limited stage small cell lung cancer
Treat limited stage small cell lung cancer with chemotherapy and radiation, and consider preventive brain radiation for better survival chances.
research Yangxuebushen Decoction prevents cyclophosphamide-induced hair loss by inhibiting hair follicle apoptosis
Yangxuebushen Decoction helps prevent hair loss from chemotherapy.
research Management of Advanced Prostate Cancer Undergoing Major Shift
New treatments are making advanced prostate cancer management more complex but also more hopeful.
research Cetuximab-Associated Elongation of the Eyelashes
Cetuximab can cause eyelash growth, which is rare but manageable.
research Inhibition of the development of metastatic squamous cell carcinoma in protein kinase C epsilon transgenic mice by alpha-difluoromethylornithine accompanied by marked hair follicle degeneration and hair loss.
Alpha-difluoromethylornithine prevents cancer in mice but causes hair loss.
research Low-dose oral minoxidil for persistent chemotherapy and radiotherapy-induced alopecia in a pediatric female patient
research Recurring Chemotherapy-Associated Alopecia Areata: Case Report and Literature Review
Chemotherapy may cause recurring hair loss due to an autoimmune response.
research TOPICAL IMMUNOTHERAPY IN DERMATOLOGY
Diphencyprone (DCP) is an effective treatment for severe alopecia areata and resistant warts, with some risks.
research Salvage Chemotherapy in Follicular Non-Hodgkin's Lymphoma: Focus on Tolerability
Balancing treatment effectiveness with side effects is crucial for relapsed follicular non-Hodgkin's lymphoma, especially in older patients.
research Streptomyces-derived nano-doxorubicin: Clinical status and patents granted
Nanoparticle delivery can reduce side effects of the cancer drug doxorubicin.